Om

HanchorBio Inc. is a biotechnology company established in 2020 and headquartered in Taipei, Taiwan. Specializing in immuno-oncology, HanchorBio is dedicated to developing next-generation biologic therapies designed to enhance and harness the immune system's ability to combat cancer. The company's core innovation lies in its proprietary Fc-Based Designer Biologics (FBDB™) technology platform, which engineers multifunctional molecules capable of simultaneously activating both innate and adaptive immune responses to target and eliminate tumors.

HanchorBio's pipeline features advanced therapeutic candidates, including HCB101—a CD47-targeting fusion protein—highlighted by recent progress into Phase 2 clinical trials across Taiwan, the United States, and China. The company operates globally with a growing presence in the United States, mainland China, and Taiwan, supported by a leadership team recognized for deep experience in biologics research and regulatory success. Through strategic partnerships and robust investment from prominent institutional investors, HanchorBio positions itself as a significant innovator within the biotechnology and pharmaceutical sectors, working to address unmet medical needs in oncology and contribute to advancements in precision immunotherapy.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I HANCHORBIO MED ENDAVU: Køb HanchorBio ($7827) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i HanchorBio, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.